Topic Highlight
Copyright ©2012 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2012; 18(18): 2161-2171
Published online May 14, 2012. doi: 10.3748/wjg.v18.i18.2161
Table 1 Overview of important pharmacodynamic studies on the clopidogrel-proton pump inhibitor interaction
StudyPPIs usedPopulationPrimary outcomeAuthor’s conclusions
Gilard et al[7] OCLA study (double-blind, placebo-controled, randomized)Omeprazole124 patients undergoing elective coronary stent implantationVASP-PRI on 7 dOmeprazole significantly decreases clopidogrel inhibitory effect
Cuisset et al[11] PACA study (prospective, randomized)Omeprazole vs Pantoprazole104 NSTE-ACS patients undergoing coronary stentingVASP-PRI/ADP-Ag after 1 moSignificantly better platelet response under pantoprazole (VASP-PRI), no difference for ADP-Ag
O’Donoghue et al[26] PRINCIPLE-TIMI 44 (post hoc analysis of a RCT)Not specified201 patients undergoing planned PCIADP AgMean inhibition of platelet aggregation significantly lower for patients on PPI
Siller-Matula et al[8] (prospective observational)Pantoprazole esomeprazole300 patients with CAD undergoing PCIVASP-PRI/ADP-Ag in the catheter laboratoryNo association of PPIs with impaired response to clopidogrel
Neubauer et al[13] (prospective observational)Pantoprazole omeprazole esomeprazole336 patients undergoing coronary stent implantationADP AgPantoprazole does not diminish the antiplatelet effectiveness of clopidogrel
Angiolillo et al[12] (placebo controlled, randomized, cross-over)Omeprazole pantoprazole282 healthy subjectsClopi H4 ADP Ag VASP-PRI after 5 dPresence of a metabolic drug-drug interaction between clopidogrel and omeprazole but not for pantoprazole